



OPEN ACCESS

Original research

Exploring the phenotype of Italian patients with ALS with intermediate *ATXN2* polyQ repeats

Adriano Chio ^{1,2}, Cristina Moglia,^{1,2} Antonio Canosa ^{1,2}, Umberto Manera,^{1,2} Maurizio Grassano ¹, Rosario Vasta ¹, Francesca Palumbo,¹ Salvatore Gallone,² Maura Brunetti,¹ Marco Barberis,³ Fabiola De Marchi,⁴ Clifton Dalgard,^{5,6} Ruth Chia,⁷ Gabriele Mora,¹ Barbara Iazzolino,¹ Laura Peotta,¹ Bryan Traynor,^{8,9} Lucia Corrado,¹⁰ Sandra D'Alfonso,¹⁰ Letizia Mazzini,⁴ Andrea Calvo ^{1,2}

► Additional supplemental material is published online only. To view, please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2022-329376>).

For numbered affiliations see end of article.

Correspondence to

Professor Adriano Chio, 'Rita Levi Montalcini' Department of Neuroscience, University of Turin, Torino 10124, Italy; achio@usa.net

Received 9 April 2022

Accepted 12 July 2022

Published Online First 25 August 2022

ABSTRACT

Objective To detect the clinical characteristics of patients with amyotrophic lateral sclerosis (ALS) carrying an intermediate *ATXN2* polyQ number of repeats in a large population-based series of Italian patients with ALS.

Methods The study population includes 1330 patients with ALS identified through the Piemonte and Valle d'Aosta Register for ALS, diagnosed between 2007 and 2019 and not carrying *C9orf72*, *SOD1*, *TARDBP* and *FUS* mutations. Controls were 1274 age, sex and geographically matched Italian subjects, identified through patients' general practitioners.

Results We found 42 cases and 4 controls with ≥ 31 polyQ repeats, corresponding to an estimated OR of 10.4 (95% CI 3.3 to 29.0). Patients with ≥ 31 polyQ repeats (*ATXN2+*) compared with those without repeat expansion (*ATXN2-*) had more frequently a spinal onset ($p=0.05$), a shorter diagnostic delay ($p=0.004$), a faster rate of ALSFRS-R progression ($p=0.004$) and King's progression ($p=0.004$), and comorbid frontotemporal dementia (7 (28.0%) vs 121 (13.4%), $p=0.037$).

ATXN2+ patients had a 1-year shorter survival (*ATXN2+* patients 1.82 years, 95% CI 1.08 to 2.51; *ATXN2-* 2.84 years, 95% CI 1.67 to 5.58, $p=0.0001$). *ATXN2* polyQ intermediate repeats was independently related to a worse outcome in Cox multivariable analysis ($p=0.006$).

Conclusions In our population-based cohort, *ATXN2+* patients with ALS have a distinctive phenotype, characterised by a more rapid disease course and a shorter survival. In addition, *ATXN2+* patients have a more severe impairment of cognitive functions. These findings have relevant implications on clinical practice, including the possibility of refining the individual prognostic prediction and improving the design of ALS clinical trials, in particular as regards as those targeted explicitly to *ATXN2*.

INTRODUCTION

Amyotrophic lateral sclerosis (ALS) is a multisystem disorder of adult life characterised by progressive degeneration of upper and lower motor neurons and frontotemporal cortex neurons. Several genes have been related to this fatal neurodegenerative disorder, accounting for 10%–20% of ALS cases.^{1,2} Among these, an intermediate-length CAG number of repeats (encoding ≥ 31 glutamines, polyQ) in the

WHAT IS ALREADY KNOWN ON THIS TOPIC

⇒ An intermediate-length CAG number of repeats (encoding ≥ 31 glutamines, polyQ) in the ataxin 2 (*ATXN2*) gene is recognised to be associated with an increased risk of developing amyotrophic lateral sclerosis (ALS). However, very few is known about the phenotypic characteristics of patients with *ATXN2* polyQ intermediate number of repeats.

WHAT THIS STUDY ADDS

⇒ Patients with *ATXN2* polyQ intermediate number of repeats had more commonly a spinal onset and were characterised by a more rapid clinical course, as shown by a 1.5-fold ALSFRS-R progression and a significantly higher King's progression at the time of diagnosis compared with patients without the expansion. In addition, patients with *ATXN2* PolyQ intermediate number of repeats were more frequently affected by frontotemporal impairment.

WHAT THIS STUDY MAY AFFECT RESEARCH, PRACTICE, OR POLICY

⇒ The identification of the specific phenotypic characteristics of patients with ALS with *ATXN2* polyQ intermediate number of repeats has many implications, including the possibility of refining the individual prognostic prediction and improving the design of ALS clinical trials, including those targeted explicitly to *ATXN2*.

ataxin 2 (*ATXN2*) gene, already known as the cause of spinocerebellar ataxia type 2 (characterised by a number of polyQ ≥ 38), is recognised to be associated with an increased risk of developing ALS and has been reported to be a modifier of survival.^{3,4} More recently, it has been reported that an intermediate number of *ATXN2* polyQ repeats can also be a modifier of frontotemporal dementia (FTD) phenotype.^{5,6} Nevertheless, the phenotypic characteristics of patients with ALS with intermediate-length CAG repeats in the *ATXN2* gene are still incompletely understood. This study aimed at detecting the clinical characteristics of patients with ALS carrying



© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

To cite: Chio A, Moglia C, Canosa A, et al. *J Neurol Neurosurg Psychiatry* 2022;**93**:1216–1220.

an intermediate number of *ATXN2* polyQ repeats in a large population-based series of Italian patients with ALS.

METHODS

The study population includes 1487 patients with ALS identified through the Piemonte and Valle d'Aosta Register for ALS, a prospective population-based register active since 1995. The characteristics of the register have been reported elsewhere.⁷ For the present paper, we considered ALS cases diagnosed between 2007 and 2019. Patients met the El Escorial revised diagnostic criteria for definite, probable and probable laboratory-supported ALS.⁸

ALSFRS-R mean monthly decline (Δ ALSFRS-R) was calculated using the following formula: $(48 - \text{ALSFRS-R score at diagnosis}) / (\text{months from onset to diagnosis})$. Similarly, weight mean monthly decline (Δ Weight) as $(\text{Weight at diagnosis} - \text{healthy body weight}) / (\text{months from onset to diagnosis})$. Finally, to have a proxy of disease spread, we calculated the mean/monthly decline of King's staging as $(\text{King's staging at diagnosis}) / (\text{months from onset to diagnosis})$.

A total of 928 patients underwent an extensive cognitive battery at the time of diagnosis. These cases were classified into five categories according to the Consensus Criteria for diagnosing frontotemporal cognitive and behavioural syndromes in ALS.⁹ The battery assessed executive function, memory, visuospatial function, language and social cognition using the following tests Letter Fluency test; Category Fluency Test; Frontal Assessment Battery; Trail Making Test A, B and B-A; Rey-Osterrieth Complex Figure Test, immediate (IR) and delayed recall (DR); Rey Auditory Verbal Learning Test (RAVL), immediate (IR) and DR; BSRT, immediate (IR) and DR; Digit Span Forward and Backward; Raven's Colored Progressive Matrices (CPM47); Story-Based Empathy Task; and Mini-Mental State Examination. The raw scores of all tests were age, sex and education-corrected using the more recent Italian normative.¹⁰

Neurobehavioral dysfunction was determined with the Frontal Systems Behavior Scale (FrSBe), using the Family-form evaluated by a close relative/caregiver (scores: normal ≤ 59 , borderline 60–64; pathological ≥ 65). For this study, we considered the change in points for each of the three domains of FrSBe (apathy, disinhibition, executive) from *before-disease* to *disease* scores. If a subject had scores reflecting a frontal systems abnormality both

in the premorbid and post-illness forms, they were considered pathological only if there was an increase of ≥ 10 points at the T-score between the two states.¹⁰ Anxiety and depression were assessed using the Hospital Anxiety and Depression Scale; the item 'I feel slowed down' was discussed with patients to have them not refer to physical disability.¹¹

Controls

Controls were 1274 age, sex and geographically matched Italian subjects, identified through patients' general practitioners.

Genetic analysis

All patients included in the study were tested for *SOD1* (all exons), *TARDBP* (exon 6), *FUS* (exons 14 and 15) mutations, and *C9orf72* intronic expansion using the methods described elsewhere.¹² However, since 1180 cases underwent whole-genome sequencing, no mutation in the other exons of *TARDBP* and *FUS* were found.

ATXN2 CAG repeat analysis

In 434 cases and 509 controls, *ATXN2* CAG repeat in exon 1 (NM_002973.3) was amplified using a fluorescent primer and sized by capillary electrophoresis on an ABI3130 genetic analyzer (Applied Biosystems, Foster City, California, USA). In 1043 cases and 765 controls, *ATXN2* CAG repeats were detected through next-generation sequencing. All subjects were screened for the *C9orf72* intronic expansion using a standard repeat-primed PCR¹³ (Renton *et al.* 2011 PMID: 21944779). Repeat lengths of ≥ 30 units with the characteristic sawtooth pattern were considered pathogenic. Whole-genome sequencing was performed at The American Genome Center located at the Uniformed Services University, Bethesda, Maryland, USA. Libraries were prepared using TruSeq DNA PCR-Free High Throughput Library Prep Kit (Illumina) per the manufacturer's instructions. Sequencing was performed on an Illumina HiSeqX10 sequencer using paired-end 150 base pair reads. A significant advantage of next-generation sequencing is its ability to reliably assay repeat expansions, such as those in *C9orf72* and *ATXN2*. *ATXN2* CAG repeats were deemed intermediate if they were in the 31–38 range. ExpansionHunter—Targeted software (V3.0.1) was used to estimate repeat lengths of known, disease-causing expansions in samples

Table 1 Demographic and clinical characteristics of patients according to *ATXN2* PolyQ intermediate number of repeats (*ATXN2+*, PolyQ ≥ 31 ; *ATXN2-*, PolyQ ≤ 30)

| | <i>ATXN2+</i> (n=42) | <i>ATXN2-</i> (n=1288) | P value |
|--|----------------------|------------------------|---------|
| Age at onset (median, IQR) | 69.6 (63.5–75.7) | 68.3 (60.3–74.4) | 0.15 |
| Gender (female) | 15 (35.7%) | 575 (44.6%) | 0.25 |
| Site of onset (bulbar) | 7 (16.7%) | 393 (30.5%) | 0.05 |
| Diagnostic delay (months, IQR) | 6.0 (3.94–10.03) | 9.04 (5.88–13.97) | 0.004 |
| ALSFRS-R score at diagnosis (median, IQR) | 42 (34.75–44) | 42 (37–45) | 0.13 |
| Δ ALSFRS-R (median points/month, IQR) | 1.00 (0.50–1.99) | 0.66 (0.31–1.33) | 0.004 |
| FVC% at diagnosis (median, IQR)* | 89 (74–105) | 91 (72–104) | 0.81 |
| Δ Weight (kg/month, median, IQR)† | 0.50 (0–1.26) | 0.28 (0–0.96) | 0.87 |
| MiToS stage at diagnosis (0/1/2/3/4) | 27/12/2/1/0 | 858/374/42/10/2 | 0.80 |
| King's state at diagnosis (1/2/3/4) | 14/14/11/3 | 530/409/293/50 | 0.59 |
| Δ King's (median points/month, IQR) | 0.25 (0.17–0.53) | 0.19 (0.10–0.34) | 0.004 |
| ALS-FTD‡ | 7 (28.0%) | 121 (13.4%) | 0.037 |

*FVC, 1222 (*ATXN2+*, 38; *ATXN2-*, 1184).

†Weight 1288 (*ATXN2+*, 40; *ATXN2-*, 1246).

‡928 cases (*ATXN2+*, 25, *ATXN2-*, 903)

Table 2 Frequency of cognitive impairment classified according to the consensus criteria for the diagnosis of frontotemporal cognitive and behavioural syndromes in ALS⁹

| | ATXN2+ (n=25) | ATXN2- (n=903) |
|------------------------|---------------|----------------|
| Cognitively normal ALS | 10 (40%) | 483 (53.5%) |
| ALSbi | – | 72 (8%) |
| ALSci | 7 (28%) | 164 (18.2%) |
| ALScbi | 1 (4%) | 63 (7%) |
| ALS-FTD | 7 (28%) | 121 (13.4%) |

In patients with ALS with ATXN2 PolyQ intermediate number of repeats ≥ 31 (ATXN2+) compared with patients with PolyQ ≤ 30 (ATXN2-). ALS-FTD was significantly more frequent in ATXN2+ patients ($p=0.037$).
ALS, amyotrophic lateral sclerosis; ALSbi, ALS with behavioural impairment; ALScbi, ALS with cognitive and behavioural impairment; ALSci, ALS with cognitive impairment; ALS-FTD, ALS with comorbid FTD.

that had undergone whole-genome sequencing.¹⁴ This algorithm has been validated using experimentally confirmed samples carrying the *C9orf72* and *ATXN2* repeat expansions. In particular, cases with ≥ 31 polyQ repeats were identified correctly with both PCR and ExpansionHunter.

Statistical methods

Multivariable analysis for survival was performed with the Cox proportional hazards model (stepwise backward) with a retention criterion of $p < 0.1$. A $p < 0.05$ was considered significant. Statistical analyses were carried out using the SPSS V.26.0 statistical package (SPSS).

RESULTS

We assessed for intermediate ATXN2 polyQ repeats 1487 patients with ALS diagnosed in Piemonte e Valle d’Aosta between 2007 and 2019. Of these, 157 were subsequently excluded from the present analysis because they carried a genetic mutation of one of the most common ALS-related genes (*C9orf72*, 97; *SOD1*, 32; *TARDBP*, 21; *FUS*, 6). We decided to exclude *C9orf72* patients from this analysis because we found in a previous paper that in patients with this mutation intermediate ATXN2 polyQ repeats do not modify survival.¹⁵ As for *SOD1*, *TARDBP* and *FUS*, we chose to also exclude these cases because of the strong influence of these genes on survival. The study was therefore performed on 1330 patients. Controls were 1274 subjects matched to cases by age, gender and geographical origin. Patients and controls did not differ for the main demographic variables (online supplemental table 1).




Figure 1 Survival from onset according to ATXN2 polyQ intermediate number of repeats. PolyQ ≥ 31 (green line) versus PolyQ ≤ 30 (blue line). Ticks indicate censored patients. $P < 0.0001$.

Table 3 Patients’ survival

| Variable | Value | HR (95% CI) | P value |
|---------------------------|-------------------------------|------------------------|---------|
| Age at onset (years) | Per each year of age at onset | 1.030 (1.024 to 1.037) | 0.0001 |
| Diagnostic delay (months) | Per each month of delay | 0.953 (0.945 to 0.962) | 0.0001 |
| Site of onset | Spinal | 1 (reference) | 0.0001 |
| | Bulbar | 1.45 (1.27–1.67) | |
| Δ ALSFRS-R | Per each point loss/month | 1.25 (1.20 to 1.29) | 0.0001 |
| Δ King’s | Per each point loss/month | 1.56 (1.16 to 2.09) | 0.003 |
| ATXN2 polyQ | <31 | 1 (reference) | 0.006 |
| | ≥ 31 | 1.58 (1.14 to 2.19) | |

Cox multivariable analysis.

In our cohort, we found 46 cases and 44 controls with 27 to 30 polyQ repeats, and 42 cases and 4 controls with ≥ 31 polyQ repeats. The estimated OR for 27–30 polyQ was 0.99 (95% CI 0.66 to 1.52). The estimated OR for ≥ 31 polyQ was 10.4 (95% CI 3.3 to 29.0). The 4 controls had 31 (3) and 32 (1) polyQ repeats. Their age ranged between 55 and 72 years. They were neurologically normal and they had no family history for neurodegenerative diseases or ataxia. The number of polyQ repeats in patients was 20 (31 repeats), 12 (32 repeats), 4 (33 repeats), 3 (34 repeats), 2 (35 repeats) and 1 (38 repeats).

Phenotype of ATXN2+ patients (table 1). Patients with intermediate ATXN2 polyQ repeats ≥ 31 polyQ repeats (ATXN2+) and those without expansion (<31 polyQ repeats) (ATXN2-) did not differ for the age at onset but ATXN2+ had more frequent spinal onset ($p=0.05$). In addition, ATXN+ patients had a shorter diagnostic delay ($p=0.004$) and a faster rate of progression as measured by Δ ALSFRS-R ($p=0.004$) and Δ King’s ($p=0.004$).

A total of 928 patients (25 ATXN2+ and 903 ATXN2-) and 129 controls underwent cognitive examination. The demographic and clinical characteristics of these patients did not differ from that of the overall cohort (online supplemental table 2). ATXN2+ patients were more commonly diagnosed as ALS-FTD (7 (28.0%) vs 121 (13.4%), $p=0.037$) (table 2).

When assessing the differences in specific tests, excluding the 128 patients with ALS-FTD, we found a significantly worse performance of ATXN2+ patients in the RAVL – Delayed Recall ($p=0.023$), the BSRT – Immediate Recall ($p=0.044$), and in the Executive Functions domain of ECAS ($p=0.034$) (online supplemental tables 3 and 4). No differences were found in the behavioural function assessed with FrSBe. Finally, no differences were found in anxiety, while depression was significantly more severe in ATXN2+ patients ($p=0.04$).

Survival analysis

ATXN2+ patients had a 1 year shorter survival (median survival time for ATXN2+ patients = 1.82 years, 95%CI 1.08 to 2.51; ATXN2- = 2.84 years, 95%CI 1.67 to 5.58, $p=0.0001$, figure 1). The Cox multivariable analysis confirmed that the ATXN2 polyQ intermediate number of repeats was independently related to a worse outcome compared with non-expanded patients in our cohort ($p=0.006$) (table 3). A separate analysis including only the patients not assessed in our previous paper³ gave similar results (data not shown).

Analysis of oligogenicity

All but two patients with ≥ 31 polyQ repeats underwent whole-genome sequencing. We extracted variant information for 47

genes previously implicated in ALS pathogenesis (see online supplemental table 5 for the list of extracted genes). The following six mutations of ALS-related genes, all in heterozygosis, of ALS-related genes were detected (one for each patient): *OPTN*: p.L111R; *SETX*: p.H476R; *CCNF*: p.R123H; *EWSR1*: p.A132S; *SETX*: p.V919I; *DTCN1*: p.A354V. Allele frequencies and predicted functional effects of identified genetic variants are reported in online supplemental table 6. Patients carrying one of these mutations (n=6) did not differ from those not carrying other genetic mutations (n=34) for any clinical characteristic but the median weight decline (Δ weight) (see online supplemental table 7).

DISCUSSION

We have assessed a large population-based cohort of Italian patients with ALS without mutations for *C9orf72*, *SOD1*, *TARDBP* and *FUS* genes to identify the clinical signature of *ATXN2* polyQ intermediate number of repeats. We have found that *ATXN2*+ patients, despite having more commonly spinal onset, were characterised by a more rapid clinical course, as shown by (1) a 1.5-fold Δ ALSFRS-R at the time of diagnosis compared with *ATXN2*- patients; (2) a shorter diagnostic delay, a factor related to a faster disease progression; and (3) a significantly higher Δ King's, indicating a more rapid spreading of symptoms from one to three body regions. The greater aggressiveness of ALS in subjects with *ATXN2* polyQ intermediate number of repeats is reflected in the 1 year shorter survival (median survival time, 1.82 vs 2.84), confirming our previous findings.³ This result was independent of relevant prognostic factors in Cox multivariable analysis. Finally, patients with *ATXN2* PolyQ intermediate number of repeats were more frequently affected by frontotemporal impairment.

ATXN2 polyQ intermediate number of repeats were first recognised as a risk factor for ALS in 2010 in a cohort of US patients (using a cut-off ≥ 27)¹⁶ and subsequently confirmed in populations of different ethnic origin,³ with the only exception of South Africans.¹⁷ Although a length of 27–33 polyQ was initially considered significantly associated with ALS, later studies have shown that the cut-off is ≥ 31 polyQ repeats. In our population, we found that the best risk cut-off for ALS is ≥ 31 polyQ since the distribution of alleles in the 27–30 polyQ repeats range was substantially similar among patients and controls.

ATXN2 is an RNA binding protein with an essential function in the nucleocytoplasmic shuttling of RNA and regulation of transcription.¹⁸ However, the pathogenic mechanism of *ATXN2* in ALS is unknown. It has been reported that *ATXN2* induces an increase of phosphorylated TDP-43 in the spinal anterior horn but not in motor cortex neurons of patients with ALS.¹⁹ Interestingly, our data show that the spinal phenotype is more common in patients with *ATXN2* polyQ intermediate number of repeats than those without expansion.

A recent paper has reported that *ATXN*+ patients (cut-off limits ≥ 31) did not show any survival difference compared with *ATXN*-.²⁰ The discrepancy with the present study is likely related to the different nature of the two cohorts, that is, the prevalent, referral centers, population in the US study (as indicated by the young age at onset (~60 years), the median survival (~3.5 years) and finally the very low percentage of patients with ALS-FTD (3.8%)) and the incident population in our study. It is therefore possible that at least a part of fast progressor patients, including those who are *ATXN*+, have not been caught in the US study. Several papers have demonstrated that prevalent and incident populations strongly differ from the clinical point of view,

including survival, supporting the notion that studies derived from clinical cohorts should be cautiously interpreted.^{21 22}

A novel finding in this paper is the identification of a correlation between *ATXN2* polyQ intermediate number of repeats in ALS and cognitive impairment. ALS-FTD was two times more frequent among the *ATXN2*+ patients (28% vs 13.4%). Furthermore, some cognitive tests related to frontal function (RAVL – delayed recall, BSRT – immediate recall, and Executive Functions domain of ECAS) were significantly more compromised in *ATXN2*+ patients. Interestingly, *ATXN2* polyQ intermediate number of repeats (using a cut-off of ≥ 27) have been recently proposed to be a modifier of the behavioural variant FTD phenotype, with earlier age at onset and more frequent parkinsonian and psychotic symptoms.^{5 6 23} However, no increased risk of developing behavioural variant FTD was reported by other studies.^{24 25} An antagonistic pleiotropic role in cognition of *ATXN2* has been identified, with a positive influence on verbal-numerical reasoning, reaction time, educational attainment and cognitive resilience,^{26 27} while in spinocerebellar ataxia 2 polyQ expansions are related to cognitive impairment in executive functions, memory and visuoconstructive skills.²⁸ Finally, a post-mortem study in patients with non-fluent primary progressive aphasia with 39 polyQ repeat expansion showed neuronal loss and gliosis, associated with a superficial laminar spongiosis, were severe in the superficial layers of the middle frontal gyrus, motor cortex, supramarginal gyrus, CA1 and the subiculum, but not in the cerebellum.²⁹

One limitation of this study is that not all patients were tested for cognitive function. However, the clinical characteristics of tested and non-tested patients were similar, excluding a selection bias. A remarkable feature of our study is its population-based nature, including some 80% of incident patients.

In conclusion, in our population-based cohort of patients of Italian ancestry, we found that patients with ALS carrying an intermediate *ATXN2* polyQ number of repeats ≥ 31 have a distinctive phenotype, characterised by a more rapid disease course, with a 1.5-fold increase of Δ ALSFRS-R rate and a higher Δ King's. Compared with *ATXN2*- patients, this greater aggressiveness resulted in a 1 year reduction in survival. In addition, *ATXN2*+ patients have a more severe impairment of cognitive functions, with relative preservation of the behavioural domain. Identifying the specific phenotypic characteristics of patients with ALS with *ATXN2* polyQ intermediate number of repeats has many implications. These include the possibility of refining the individual prognostic prediction and improving the design of ALS clinical trials, including those targeted explicitly to *ATXN2*.

Author affiliations

- ¹Rita Levi Montalcini¹ Department of Neuroscience, University of Turin, Torino, Italy
- ²Neurology 1, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
- ³Genetics, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
- ⁴Neurology, Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara, Italy
- ⁵Department of Anatomy, Physiology & Genetics, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- ⁶The American Genome Center, Collaborative Health Initiative Research Program, Uniformed Services University of the Health Sciences, Bethesda, Maryland, USA
- ⁷Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, NIH, Porter Neuroscience Research Center, Bethesda, Maryland, USA
- ⁸Neuromuscular Diseases Research Section, Laboratory of Neurogenetics, National Institute on Aging, Bethesda, Maryland, USA
- ⁹Department of Neurology, Johns Hopkins, Baltimore, Maryland, USA
- ¹⁰Department of Health Sciences Interdisciplinary Research Center of Autoimmune Diseases, University of Eastern Piedmont Amedeo Avogadro School of Medicine, Novara, Italy

Contributors AC had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: AC, CM, AC, UM, MG, RV, FP, SG, MB, MB, FDM, CD, RC, GM, BT, LC, SD'A, LM, AC. Acquisition, analysis, or interpretation of data: AC, CM, AC, UM, MG, RV, FP, SG, MB, MB, FDM, CD, RC, GM, BT, LC, SD'A, LM, AC. Drafting of the manuscript: AC, CM, AC, BT, SD'A, LM, AC. Critical revision of the manuscript for important intellectual content: AC, CM, AC, UM, MG, RV, FP, SG, MB, MB, FDM, CD, RC, GM, BT, LC, SD'A, LM, AC. Obtained funding: BT, AC. Administrative, technical, or material support: MG, FP, SG, MB. Study supervision: AC, CM, AC, FD'A, LM, AC. AC is responsible for the overall content as guarantor.

Funding This work was supported by the Italian Ministry of Health (Ministero della Salute, Ricerca Sanitaria Finalizzata, grant RF-2016-02362405); the Progetti di Rilevante Interesse Nazionale program of the Ministry of Education, University and Research (grant 2017SNW5MB); the European Commission's Health Seventh Framework Programme (FP7/2007–2013 under grant agreement 259867); the Horizon 2020 Programme (project Brainteaser under grant agreement 101017598); and the Joint Programme–Neurodegenerative Disease Research (Strength, ALS-Care and Brain-Mend projects), granted by Italian Ministry of Education, University and Research. This work was supported in part by the Intramural Research Programs of the National Institute on Aging (grant Z01-AG000949-02). This study was performed under the Department of Excellence grant of the Italian Ministry of University and Research to the "Rita Levi Montalcini" Department of Neuroscience, University of Torino, Italy, and to the Department of Health Sciences, University of Eastern Piedmont, Novara, Italy.

Disclaimer The funders had no role in data collection or analysis and did not participate in writing or approving the manuscript.

Competing interests Adriano Chiò serves on scientific advisory boards for Mitsubishi Tanabe, Biogen, Roche, Denali Pharma, Cytokinetics, Lilly, and Amylyx Pharmaceuticals and has received a research grant from Biogen. Cristina Moglia, Antonio Canosa, Umberto Manera, Maurizio Grassano, Rosario Vasta, Francesca Palumbo, Salvatore Gallone, Maura Brunetti, Fabiola De Marchi, Clifton L. Dalgard, Ruth Chia, Gabriele Mora, Lucia Corrado, Sandra D'Alfonso, Letizia Mazzini no disclosures. Dr Traynor holds the US, Canadian, and European patents on the clinical testing and therapeutic intervention for the hexanucleotide repeat expansion in C9orf72. Andrea Calvo has received a research grant from Cytokinetics.

Patient consent for publication Not applicable.

Ethics approval This study involves human participants and was approved by Comitato Etico Azienda Ospedaliero-Universitaria Città della Salute e della Scienza, Torino, and Comitato Etico Azienda Ospedaliero-Universitaria Maggiore della Carità, Novara (protocol number #0038876). Patients and controls provided written informed consent before enrolment. The databases were anonymised according to the Italian law for protecting privacy.

Provenance and peer review Not commissioned; externally peer reviewed.

Data availability statement Data are available upon reasonable request. Data will be available upon reasonable request by interested researchers.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

ORCID iDs

Adriano Chiò <http://orcid.org/0000-0001-9579-5341>
Antonio Canosa <http://orcid.org/0000-0001-5876-4079>
Maurizio Grassano <http://orcid.org/0000-0001-6714-6897>
Rosario Vasta <http://orcid.org/0000-0002-0393-4736>
Andrea Calvo <http://orcid.org/0000-0002-5122-7243>

REFERENCES

- Goutman SA, Hardiman O, Al-Chalabi A, *et al*. Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. *Lancet Neurol* 2022;21:465–79.
- Grassano M, Calvo A, Moglia C, *et al*. Mutational analysis of known ALS genes in an Italian population-based cohort. *Neurology* 2021;96:e600–9.
- Chiò A, Calvo A, Moglia C, *et al*. ATXN2 polyQ intermediate repeats are a modifier of ALS survival. *Neurology* 2015;84:251–8.
- Sproviero W, Shatunov A, Stahl D, *et al*. ATXN2 trinucleotide repeat length correlates with risk of ALS. *Neurobiol Aging* 2017;51:178.e1–178.e9.
- Fournier C, Anquetil V, Camuzat A, *et al*. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. *Acta Neuropathol Commun* 2018;6:41.
- Rubino E, Mancini C, Boschi S, *et al*. ATXN2 intermediate repeat expansions influence the clinical phenotype in frontotemporal dementia. *Neurobiol Aging* 2019;73:231.e7–231.e9.
- Chiò A, Mora G, Moglia C, *et al*. Secular trends of amyotrophic lateral sclerosis: the Piemonte and Valle d'Aosta register. *JAMA Neurol* 2017;74:1097–104.
- Brooks BR, Miller RG, Swash M. World Federation of Neurology Research group on motor neuron diseases. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. *Amyotroph Lateral Scler Other Motor Neuron Disord* 2000;1:293–9.
- Strong MJ, Abrahams S, Goldstein LH. Revised diagnostic criteria. *Amyotroph Lateral Scler Frontotemporal Degener* 2017;18:153–74.
- Iazzolino B, Peotta L, Zucchetti JP, *et al*. Differential neuropsychological profile of patients with amyotrophic lateral sclerosis with and without C9orf72 mutation. *Neurology* 2021;96:e141–52.
- Montuschi A, Iazzolino B, Calvo A, *et al*. Cognitive correlates in amyotrophic lateral sclerosis: a population-based study in Italy. *J Neurol Neurosurg Psychiatry* 2015;86:168–73.
- Chiò A, Calvo A, Mazzini L, *et al*. Extensive genetics of ALS: a population-based study in Italy. *Neurology* 2012;79:1983–9.
- Renton AE, Majounie E, Waite A, *et al*. A hexanucleotide repeat expansion in C9orf72 is the cause of chromosome 9p21-linked ALS-FTD. *Neuron* 2011;72:257–68.
- Dolzhenko E, Deshpande V, Schlesinger F, *et al*. ExpansionHunter: a sequence-graph-based tool to analyze variation in short tandem repeat regions. *Bioinformatics* 2019;35:4754–6.
- Chiò A, Mora G, Sabatelli M, *et al*. ATXN2 is not a regulatory gene in Italian amyotrophic lateral sclerosis patients with C9orf72 GGGGCC expansion. *Neurobiol Aging* 2016;39:218.e5–218.e8.
- Elden AC, Kim H-J, Hart MP, *et al*. Ataxin-2 intermediate-length polyglutamine expansions are associated with increased risk for ALS. *Nature* 2010;466:1069–75.
- Nel M, Mavundla T, Gultig K, *et al*. Repeats expansions in ATXN2, NOPS6, NIPA1 and ATXN1 are not associated with ALS in Africans. *IBRO Neurosci Rep* 2021;10:130–5.
- Zhao M, Kim JR, van Bruggen R, *et al*. RNA-binding proteins in amyotrophic lateral sclerosis. *Mol Cells* 2018;41:818–29.
- Yang Y, Halliday GM, Kiernan MC, *et al*. TDP-43 levels in the brain tissue of ALS cases with and without C9ORF72 or ATXN2 gene expansions. *Neurology* 2019;93:e1748–55.
- Glass JD, Dewan R, Ding J, *et al*. ATXN2 intermediate expansions in amyotrophic lateral sclerosis. *Brain* 2022;awac167.
- Sorenson EJ, Mandrekar J, Crum B, *et al*. Effect of referral bias on assessing survival in ALS. *Neurology* 2007;68:600–2.
- Logrosino G, Marin B, Piccininni M, *et al*. Referral bias in ALS epidemiological studies. *PLoS One* 2018;13:e0195821.
- Rosas I, Martínez C, Clarimón J, *et al*. Role of ATXN1, ATXN2, and HTT intermediate repeats in frontotemporal dementia and Alzheimer's disease. *Neurobiol Aging* 2020;87:139.e1–139.e7.
- Ross OA, Rutherford NJ, Baker M, *et al*. Ataxin-2 repeat-length variation and neurodegeneration. *Hum Mol Genet* 2011;20:3207–12.
- Lattante S, Millicamps S, Stevanin G, *et al*. Contribution of ATXN2 intermediary polyQ expansions in a spectrum of neurodegenerative disorders. *Neurology* 2014;83:990–5.
- Fitzgerald J, Fahey L, Holleran L, *et al*. Thirteen independent genetic loci associated with preserved processing speed in a study of cognitive resilience in 330,097 individuals in the UK Biobank. *Genes* 2022;13:122.
- Davies G, Marioni RE, Liewald DC, *et al*. Genome-wide association study of cognitive functions and educational attainment in UK Biobank (N=112 151). *Mol Psychiatry* 2016;21:758–67.
- Gigante AF, Lelli G, Romano R, *et al*. The relationships between ataxia and cognition in spinocerebellar ataxia type 2. *Cerebellum* 2020;19:40–7.
- Fournier C, Anquetil V, Camuzat A, *et al*. Interrupted CAG expansions in ATXN2 gene expand the genetic spectrum of frontotemporal dementias. *Acta Neuropathol Commun* 2018;6:41.